S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
Log in

NASDAQ:PULMPulmatrix Stock Price, Forecast & News

$1.26
-0.02 (-1.56 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.20
Now: $1.26
$1.38
50-Day Range
$0.92
MA: $1.37
$1.67
52-Week Range
$0.61
Now: $1.26
$1.92
Volume1.38 million shs
Average Volume1.29 million shs
Market Capitalization$25.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Read More
Pulmatrix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.91 million
Book Value$0.55 per share

Profitability

Net Income$-20,600,000.00

Miscellaneous

Employees22
Market Cap$25.86 million
Next Earnings Date5/20/2020 (Estimated)
OptionableOptionable

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.


Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

How has Pulmatrix's stock been impacted by COVID-19 (Coronavirus)?

Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PULM shares have decreased by 8.7% and is now trading at $1.26. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Pulmatrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pulmatrix.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Pulmatrix.

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) issued its quarterly earnings results on Friday, November, 1st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.16. The biotechnology company earned $1.41 million during the quarter. View Pulmatrix's earnings history.

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Pulmatrix shares reverse split on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PULM?

1 Wall Street analysts have issued 1 year price targets for Pulmatrix's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Pulmatrix's stock price to reach $10.00 in the next year. This suggests a possible upside of 693.7% from the stock's current price. View analysts' price targets for Pulmatrix.

Has Pulmatrix been receiving favorable news coverage?

Headlines about PULM stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pulmatrix earned a news impact score of -3.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutPulmatrix.

Are investors shorting Pulmatrix?

Pulmatrix saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,159,800 shares, an increase of 37.4% from the February 27th total of 843,900 shares. Based on an average trading volume of 454,200 shares, the short-interest ratio is currently 2.6 days. Currently, 6.0% of the company's stock are short sold. View Pulmatrix's Current Options Chain.

Who are some of Pulmatrix's key competitors?

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Neovasc (NVCN), Verastem (VSTM), Cronos Group (CRON), Biopharmx (BPMX), Biocept (BIOC), Evoke Pharma (EVOK), Novavax (NVAX) and Rexahn Pharmaceuticals (REXN).

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the following people:
  • Dr. Robert W. Clarke, CEO, Pres & Director (Age 50)
  • Mr. William E. Duke Jr., CFO, Treasurer & Sec. (Age 47)
  • Dr. James M. Roach, Consultant (Age 59)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 70)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 58)

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $1.26.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $25.86 million and generates $7.91 million in revenue each year. The biotechnology company earns $-20,600,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Pulmatrix employs 22 workers across the globe. View additional information about Pulmatrix.

What is Pulmatrix's official website?

The official website for Pulmatrix is http://www.pulmatrix.com/.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]

This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel